#France #Embolization #Guerbet #Villepinte #Lipiodol

Guerbet Achieves Major Milestone for Lipiodol® in Vascular Embolization

Guerbet, a prominent global player in medical imaging, has recently announced a pivotal achievement in the realm of vascular embolization with their product Lipiodol® Ultra Fluid. This development stems from a successful worksharing procedure involving several member states of the European Union, marking a transformative step in the field of interventional radiology.

Advances in Interventional Radiology

The newly approved indication for Lipiodol® pertains to both peripheral and central vascular embolization procedures. These procedures employ surgical glues based on cyanoacrylate that are compatible with Lipiodol® Ultra Fluid. This compatibility allows for enhanced visualization during the procedures, enabling medical professionals to better tailor the polymerization times for optimal results. These advancements signify an essential regulatory step that paves the way for gaining the necessary national authorizations to modify existing market authorizations.

Enhanced Clinical Relevance

Lipiodol® has been demonstrated to be a significant product for interventional radiology protocols, confirming its clinical relevance in minimally invasive procedures. The regulatory advancement comes as a welcome enhancement, authorized for use alongside established cyanoacrylate-based surgical adhesives during embolization. As a result, healthcare professionals can now integrate Lipiodol® into their therapeutic strategies with precise usage instructions, backing its recognized properties of radio-opacity and controlled viscosity.

The Importance of Vascular Embolization

Vascular embolization is rapidly becoming a widely recognized, safe, and effective minimally invasive technique across Europe, backed by multiple scientific recommendations. The inclusion of Lipiodol® in these procedures will expand its application in treating various conditions, including:

• - Prostatic artery embolization in benign prostatic hyperplasia
• - Treatment of varicoceles or varicose veins
• - Management of hemorrhages
• - Certain selected vascular anomalies

The data presented to support the new indication revealed several promising outcomes, including:

• - Minimal risk of major complications
• - Real-time imaging guidance improving procedural accuracy
• - High adaptability to individual anatomical and clinical situations

Insights from Leadership

François Convenant, Senior Vice President of Interventional Radiology at Guerbet, remarked, “This regulatory milestone for Lipiodol® in vascular embolization signifies an important step forward for our discipline. Its radio-opacity and physicochemical properties allow for more controlled, predictable, and safer embolization procedures. This indication formalizes years of clinical practice and opens the door to harmonized embolization techniques across Europe.”

Scientific Foundation and Clinical Impact

The foundation of interventional radiology increasingly relies on embolic agents offering precision, speed, and durability. In this context, Lipiodol® and cyanoacrylate-based adhesives become a controllable liquid embolic agent known for real-time visualization during injection, enabling immediate confirmation of vascular occlusion. Its adjustable viscosity and modifiable polymerization time make it suitable for both proximal and distal vessels, delivering a permanent and efficient occlusion, ultimately reducing the necessity for repeated procedures.

Commitment to Healthcare Professionals

Guerbet is dedicated to bolstering its support for interventional radiology teams by providing:

• - Strong scientific and clinical support
• - Dedicated medical training programs
• - Increased on-site presence
• - Reliable solutions designed to enhance patient care quality and safety, while maintaining economic efficiency for healthcare facilities.

About Guerbet

At Guerbet, we strive to forge lasting connections that enhance the quality of life for individuals. As a global leader in medical imaging, we offer a diverse range of pharmaceuticals, medical devices, and digital solutions driven by artificial intelligence for diagnostic and interventional imaging. Celebrating 100 years as pioneers in contrast products, the company employs over 2,746 staff globally and commits 10% of its annual revenue to research and development across four centers located in France and the United States. Guerbet (GBT) is publicly traded on Euronext Paris, with a reported revenue of €786 million in 2025. Visit www.guerbet.com for more information.

Contact:
Matthieu Bruneau, Institutional Communication Manager
Email: [email protected]